Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
22,273,676
-
Share change
-
+2,926
-
Total reported value
-
$330,912,225
-
Put/Call ratio
-
180%
-
Price per share
-
$14.85
-
Number of holders
-
131
-
Value change
-
-$1,999,524
-
Number of buys
-
53
-
Number of sells
-
62
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT) as of Q3 2021
As of 30 Sep 2021,
INTERCEPT PHARMACEUTICALS IN - COM (ICPT) was held by
131 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
22,273,676 shares.
The largest 10 holders included
STATE STREET CORP, VANGUARD GROUP INC, FMR LLC, BlackRock Inc., Point72 Asset Management, L.P., EULAV Asset Management, Samsara BioCapital, LLC, MACQUARIE GROUP LTD, JACOBS LEVY EQUITY MANAGEMENT, INC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
131
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.